Literature DB >> 15273138

Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.

Andriani C Patera1, Frederick Menzel, Craig Jackson, Joan K Brieland, Judy Halpern, Roberta Hare, Anthony Cacciapuoti, David Loebenberg.   

Abstract

Using an inhalation model of pulmonary aspergillosis, we observed modest differences in the survival rates of mice treated with granulocyte colony-stimulating factor (G-CSF) and posaconazole (POS) and those treated with POS alone. This finding is in contrast to a previous report that suggested that G-CSF had a significant antagonistic effect on the antifungal activity of POS.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15273138      PMCID： PMC478512          DOI： 10.1128/AAC.48.8.3154-3158.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Device for inhalation exposure of animals to spores.

Authors:  W R PIGGOTT; C W EMMONS
Journal:  Proc Soc Exp Biol Med       Date:  1960-04

2.  Effect of combination therapy with recombinant human granulocyte colony-stimulating factor (rG-CSF) and antibiotics in neutropenic mice unresponsive to antibiotics alone.

Authors:  M Matsumoto; S Matsubara; T Yokota
Journal:  J Antimicrob Chemother       Date:  1991-09       Impact factor: 5.790

3.  Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice.

Authors:  A Polak-Wyss
Journal:  Mycoses       Date:  1991 Mar-Apr       Impact factor: 4.377

4.  Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice.

Authors:  A Polak-Wyss
Journal:  Mycoses       Date:  1991 May-Jun       Impact factor: 4.377

5.  Induction and expression of cell-mediated immune responses in inbred mice infected with Coccidioides immitis.

Authors:  R A Cox; W Kennell; L Boncyk; J W Murphy
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

6.  Granulocyte colony stimulating factor therapy of experimental cryptococcal meningitis.

Authors:  J R Graybill; R Bocanegra; C Lambros; M F Luther
Journal:  J Med Vet Mycol       Date:  1997 Jul-Aug

7.  Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice.

Authors:  B J Kullberg; M G Netea; J H Curfs; M Keuter; J F Meis; J W van der Meer
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

8.  Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans.

Authors:  A L Baltch; R P Smith; M A Franke; W J Ritz; P B Michelsen; L H Bopp
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon-gamma and granulocyte-colony-stimulating factor.

Authors:  J H Rex; S C Bhalla; D M Cohen; J P Hester; S E Vartivarian; E J Anaissie
Journal:  Transfusion       Date:  1995-07       Impact factor: 3.157

10.  Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.

Authors:  Cristina Gil-Lamaignere; Emmanuel Roilides; Juan Mosquera; Avgi Maloukou; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more
  2 in total

1.  Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation.

Authors:  Amar Safdar
Journal:  Curr Fungal Infect Rep       Date:  2010-03

Review 2.  Modulating host immune responses to fight invasive fungal infections.

Authors:  James E Scriven; Mark W Tenforde; Stuart M Levitz; Joseph N Jarvis
Journal:  Curr Opin Microbiol       Date:  2017-11-15       Impact factor: 7.934
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.